# AZENTA, INC. (AZTA) FY2026 Q3 Balance Sheet

- Company: AZENTA, INC. (AZTA)
- Period: As of 2026-06-30
- Filing: Q3 FY2026 10-Q, filed 2026-08-06, accession number 0001628280-26-054295
- Page: https://plicit.ai/financials/azta/fy2026-q3-balance-sheet
- Chart image: https://plicit.ai/charts/azta-fy2026-q3-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

- **Assets**: 1,876,211,000 US dollars
- **Current assets**: 681,351,000 US dollars
- **Non-current assets**: 1,194,860,000 US dollars
- **Liabilities**: 366,082,000 US dollars
- **Current liabilities**: 272,574,000 US dollars
- **Non-current liabilities**: 93,508,000 US dollars
- **Equity**: 1,510,129,000 US dollars
- **Cash and cash equivalents**: 189,654,000 US dollars
- **Accounts receivable, net of allowance for expected credit losses ($3,842 and $4,649, respectively)**: 143,675,000 US dollars
- **Short-term marketable securities**: 136,143,000 US dollars
- **Inventories**: 79,082,000 US dollars
- **Current assets held for sale**: 71,387,000 US dollars
- **Prepaid expenses and other current assets**: 53,150,000 US dollars
- **Refundable income taxes**: 5,846,000 US dollars
- **Short-term restricted cash**: 2,414,000 US dollars
- **Goodwill**: 547,457,000 US dollars
- **Long-term marketable securities**: 196,087,000 US dollars
- **Property, plant and equipment, net**: 172,427,000 US dollars
- **Intangible assets, net**: 85,688,000 US dollars
- **Noncurrent assets held for sale**: 76,689,000 US dollars
- **Operating lease right-of-use assets**: 61,421,000 US dollars
- **Long-term income taxes receivable**: 45,600,000 US dollars
- **Other assets**: 8,997,000 US dollars
- **Long-term deferred tax assets**: 494,000 US dollars
- **Accounts payable**: 39,381,000 US dollars
- **Deferred revenue**: 36,041,000 US dollars
- **Customer deposits**: 35,355,000 US dollars
- **Accrued expenses and other current liabilities**: 34,249,000 US dollars
- **Accrued compensation and benefits**: 30,965,000 US dollars
- **Current liabilities held for sale**: 29,326,000 US dollars
- **Derivative liability**: 28,435,000 US dollars
- **Deposit received for the sale of B Medical Systems business**: 28,000,000 US dollars
- **Accrued income taxes payable**: 6,775,000 US dollars
- **Accrued warranty and retrofit costs**: 4,047,000 US dollars
- **Long-term operating lease liabilities**: 53,967,000 US dollars
- **Long-term deferred tax liabilities**: 15,836,000 US dollars
- **Noncurrent liabilities held for sale**: 12,980,000 US dollars
- **Other long-term liabilities**: 10,725,000 US dollars
- **Retained earnings**: 1,246,182,000 US dollars
- **Additional paid-in capital**: 493,071,000 US dollars
- **Common stock, $0.01 par value - 125,000,000 shares authorized, 57,226,616 shares issued and 43,764,747 shares outstanding at June 30, 2026; 59,320,848 shares issued and 45,858,979 shares outstanding at September 30, 2025**: 572,000 US dollars
- **Preferred stock, $0.01 par value - 1,000,000 shares authorized, no shares issued or outstanding**: 0 US dollars
- **Treasury stock, at cost - 13,461,869 shares at June 30, 2026 and September 30, 2025**: negative 200,956,000 US dollars
- **Accumulated other comprehensive loss**: negative 28,740,000 US dollars
- **Gross equity (calculated)**: 1,739,825,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.